Drug Profile


Alternative Names: Decitabine deoxyguanosine; Decitabine deoxyguanosine dinucleotide; S-110; SGI-110

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator SuperGen
  • Developer Astex Pharmaceuticals; Columbia University; Genentech; Groupe Francophone des Myelodysplasies; John Hopkins University; Weill Cornell Medical College
  • Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Furans; Purine nucleosides; Ribonucleosides; Small molecules; Triazines
  • Mechanism of Action Antimetabolites; DNA cytosine 5 methyltransferase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase II Hepatocellular carcinoma; Myeloproliferative disorders; Ovarian cancer; Solid tumours
  • Phase I/II Bladder cancer; Colorectal cancer
  • Phase I Malignant melanoma; Small cell lung cancer
  • Preclinical Chronic lymphocytic leukaemia

Most Recent Events

  • 15 Mar 2017 Phase-I clinical trials in Small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (SC) (NCT03085849)
  • 10 Jan 2017 Phase-II clinical trials in Solid tumours in United Kingdom (SC) before January 2017 (Astex Pharmaceuticals pipeline, January 2017)
  • 20 Dec 2016 Astex Pharmaceuticals, Merck Sharp & Dohme, Institute of Cancer Research, United Kingdom and Royal Marsden NHS Foundation Trust plan the phase I HyPeR trial for Solid tumours, including Prostate cancer and Non-small cell lung cancer (Late-stage disease, Combination therapy, Second-line therapy or greater) in United Kingdom (SC) (NCT02998567)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top